分子量:32 kDa

纯度:>95% as determined by SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the Human CEACAM-6, His Tag by the LAL method.

Buffer:PBS, pH7.4

生物活性:Measured by the ability of the immobilized protein to support the adhesion of calcium ionophore treated human neutrophils. When 200000 cells/well are added to CEACAM6 coated plates (10 μg/mL, 100 μL/well), 45-70% of the cells will adhere after 20 minutes at 37℃.

产品特性:Human CEACAM-6, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 32 kDa. The predicted N-terminus is Lys 35. The reducing (R) protein migrates as 35-65 kDa in SDS-PAGE  due to glycosylation.

产品背景:Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) is also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.